Total Payments
$77,175
2024 Payments
$18,898
Companies
18
Transactions
93
Medicare Patients
962
Medicare Billing
$164,915
Payment Breakdown by Category
Consulting$50,526 (65.5%)
Research$25,660 (33.2%)
Food & Beverage$989.47 (1.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $50,526 | 64 | 65.5% |
| Unspecified | $25,660 | 13 | 33.2% |
| Food and Beverage | $989.47 | 16 | 1.3% |
Payments by Type
General
$51,516
80 transactions
Research
$25,660
13 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca UK Limited | $35,706 | 45 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $18,732 | 8 | $0 (2024) |
| Eisai Inc. | $6,342 | 7 | $0 (2024) |
| AstraZeneca AB | $4,604 | 6 | $0 (2021) |
| UCB Biosciences Inc. | $3,556 | 2 | $0 (2023) |
| BIOVERATIV THERAPEUTICS INC. | $1,625 | 4 | $0 (2020) |
| SANOFI US SERVICES INC. | $1,500 | 1 | $0 (2019) |
| Regeneron Pharmaceuticals, Inc. | $1,360 | 2 | $0 (2023) |
| UCB SA | $1,063 | 1 | $0 (2022) |
| Eli Lilly and Company | $1,062 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $18,898 | 21 | AstraZeneca UK Limited ($15,215) |
| 2023 | $14,174 | 9 | Novartis Pharmaceuticals Corporation ($8,670) |
| 2022 | $19,455 | 16 | AstraZeneca UK Limited ($8,251) |
| 2021 | $16,682 | 21 | AstraZeneca UK Limited ($8,025) |
| 2020 | $5,625 | 10 | AstraZeneca UK Limited ($1,750) |
| 2019 | $1,500 | 1 | SANOFI US SERVICES INC. ($1,500) |
| 2018 | $329.15 | 5 | E.R. Squibb & Sons, L.L.C. ($179.90) |
| 2017 | $511.25 | 10 | E.R. Squibb & Sons, L.L.C. ($159.14) |
All Payment Transactions
93 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 12/19/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 12/09/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $637.50 | General |
| 12/09/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $637.50 | General |
| 11/14/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $1,700.00 | General |
| 09/23/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $1,275.00 | General |
| 09/23/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $1,275.00 | General |
| 09/23/2024 | Eisai Inc. | — | Consulting Fee | Cash or cash equivalent | $1,275.00 | General |
| 09/16/2024 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $1,841.67 | Research |
| Study: A first-in-human, randomized, participant and investigator blinded, placebo-controlled, single ascending dose with interleaved cohorts and multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of YMI024 in healthy participants | ||||||
| 09/16/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $566.67 | General |
| 09/16/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $566.67 | General |
| 09/16/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $566.67 | General |
| 09/16/2024 | Eisai Inc. | — | Consulting Fee | Cash or cash equivalent | $566.66 | General |
| 08/01/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 05/14/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 05/14/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 03/20/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $680.00 | General |
| 03/20/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $680.00 | General |
| 03/20/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $680.00 | General |
| 03/18/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 02/19/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 08/17/2023 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $510.00 | General |
| 08/17/2023 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $510.00 | Research |
| Study: A Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adult Participants | ||||||
| 07/17/2023 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $1,275.00 | General |
| 05/24/2023 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $850.00 | Research |
| Study: A Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adult Participants | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A first-in-human, randomized, participant- and investigator-blinded, placebo-controlled, two-part, single ascending intravenous dose study, to assess the safety, tolerability, and pharmacokinetics of VHB937 in healthy non-Japanese and Japanese adults | Novartis Pharmaceuticals Corporation | $7,990 | 1 |
| A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT-, INVESTIGATOR-, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) | UCB Biosciences Inc. | $3,556 | 2 |
| A 3-PART FIRST-IN-HUMAN STUDY CONSISTING OF RANDOMIZED, DOUBLE-BLINDED, PLACEBOCONTROLLED, SINGLE AND MULTIPLE ASCENDING ORAL DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RHH646, AND A RANDOMIZED, OPEN-LABEL | Novartis Pharmaceuticals Corporation | $3,008 | 1 |
| A FIRST-IN-HUMAN, RANDOMIZED, PARTICIPANT- AND INVESTIGATOR-BLINDED, PLACEBO-CONTROLLED, TWO-PART, SINGLE ASCENDING INTRAVENOUS DOSE STUDY, TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF VHB937 IN HEALTHY NON-JAPANESE AND JAPANESE ADULTS | Novartis Pharmaceuticals Corporation | $2,196 | 1 |
| A FIRST-IN-HUMAN, RANDOMIZED, PARTICIPANT- AND INVESTIGATOR-BLINDED, PLACEBO CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF XEP527 IN HEALTHY PARTICIPANTS | Novartis Pharmaceuticals Corporation | $1,850 | 1 |
| A first-in-human, randomized, participant and investigator blinded, placebo-controlled, single ascending dose with interleaved cohorts and multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of YMI024 in healthy participants | Novartis Pharmaceuticals Corporation | $1,842 | 1 |
| A Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adult Participants | Regeneron Pharmaceuticals, Inc. | $1,360 | 2 |
| A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT-, INVESTIGATOR-, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AN | UCB SA | $1,063 | 1 |
| A PHASE 1, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, SINGLE-ASCENDING DOSE STUDY OF LY3844583 IN HEALTHY PARTICIPANTS, AND MULTIPLE-DOSE STUDY OF LY3844583 IN HEALTHY PARTICIPANTS AND PATIENTS WITH ATOPIC DERMATITIS | Eli Lilly and Company | $1,062 | 1 |
| A RANDOMIZED, PARTICIPANT AND INVESTIGATOR-BLINDED, PLACEBO-CONTROLLED FIRST-IN-HUMAN STUDY TO ASSESS THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE AND MULTIPLE ASCENDING DOSES OF NCJ424 IN HEALTHY ADULT PARTICIPANTS | Novartis Pharmaceuticals Corporation | $1,054 | 1 |
| A first-in-human, randomized, participant- and investigator-blinded, placebo controlled, single and multiple ascending dose study to assess the safety, tolerability, and pharmacokinetics of XEP527 in healthy participants | Novartis Pharmaceuticals Corporation | $680.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 291 | 659 | $129,789 | $50,106 |
| 2022 | 4 | 171 | 410 | $80,618 | $30,442 |
| 2021 | 4 | 217 | 452 | $68,366 | $37,521 |
| 2020 | 6 | 283 | 594 | $83,984 | $46,846 |
Total Patients
962
Total Services
2,115
Medicare Billing
$164,915
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 65 | 378 | $60,278 | $25,190 | 41.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 69 | 70 | $27,931 | $9,258 | 33.1% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 65 | 66 | $15,702 | $6,330 | 40.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 42 | 76 | $10,854 | $3,621 | 33.4% |
| 99236 | Initial hospital care with same-day admission and discharge with high level of medical decision making, per day, if using time, at least 85 minutes | Facility | 2023 | 14 | 14 | $6,293 | $2,323 | 36.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 24 | 29 | $6,070 | $2,285 | 37.6% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 12 | 26 | $2,661 | $1,100 | 41.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 66 | 298 | $45,255 | $17,544 | 38.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 43 | 46 | $19,464 | $7,131 | 36.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 47 | 50 | $11,291 | $4,397 | 38.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 15 | 16 | $4,608 | $1,371 | 29.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 72 | 290 | $32,190 | $17,826 | 55.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 63 | 64 | $19,968 | $10,809 | 54.1% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 65 | 66 | $11,088 | $6,057 | 54.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 17 | 32 | $5,120 | $2,828 | 55.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 87 | 348 | $38,628 | $21,610 | 55.9% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 86 | 88 | $14,784 | $8,195 | 55.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 45 | 46 | $14,352 | $7,904 | 55.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 41 | 75 | $12,000 | $6,788 | 56.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 13 | 13 | $2,756 | $1,546 | 56.1% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 11 | 24 | $1,464 | $802.28 | 54.8% |
About Dr. Joseph Dellinger, MD
Dr. Joseph Dellinger, MD is a Internal Medicine healthcare provider based in Pasadena, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/16/2014. The National Provider Identifier (NPI) number assigned to this provider is 1740691377.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joseph Dellinger, MD has received a total of $77,175 in payments from pharmaceutical and medical device companies, with $18,898 received in 2024. These payments were reported across 93 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($50,526).
As a Medicare-enrolled provider, Dellinger has provided services to 962 Medicare beneficiaries, totaling 2,115 services with total Medicare billing of $164,915. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Pasadena, CA
- Active Since 05/16/2014
- Last Updated 06/24/2021
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1740691377
Products in Payments
- BIVV020 (Drug) $1,500
- ELIQUIS (Drug) $381.75
- Avance Nerve Graft (Device) $149.07
- Aimovig (Biological) $117.92
- SAMSCA (Drug) $114.40
- COSENTYX (Biological) $112.80
- TECENTRIQ (Biological) $96.86
- Victoza (Drug) $16.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Pasadena
Dr. Yuan Yuan, M.d., Ph.d, M.D., PH.D
Internal Medicine — Payments: $523,801
Internal Medicine $523,801
Christopher Dagher, M.d, M.D
Internal Medicine — Payments: $103,615
Internal Medicine $103,615
Peter Haddad, M.d, M.D
Internal Medicine — Payments: $87,600
Internal Medicine $87,600
Dr. Andrew Williams, M.d, M.D
Internal Medicine — Payments: $85,273
Internal Medicine $85,273
Dr. Helen Moon, M.d, M.D
Internal Medicine — Payments: $61,882
Internal Medicine $61,882
John Debeixedon, M D, M D
Internal Medicine — Payments: $50,465
Internal Medicine $50,465